Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Diana Riklis Family is a private investment entity and family office that focuses on the life sciences and biotechnology sectors. Led by Diana Riklis, a prominent investor and board member of UroGen Pharma, the group provides strategic capital to companies developing innovative therapies in oncology, urology, and other high-impact medical fields. The entity often co-invests with leading venture capital firms and has been involved in the growth of several successful biotech companies, including Kite Pharma and Allogene Therapeutics. Based in New York, the Diana Riklis Family plays an active role in the biopharmaceutical ecosystem through both direct investments and board representation. Its portfolio reflects a commitment to advancing cutting-edge medical research and commercializing transformative healthcare solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Diana Riklis Family.